Yue Li

Yue Li


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
XGXue Gong
Xue Gong
TDTuozhou Dong
Tuozhou Dong
MNMing Niu
Ming Niu
XLXiaoshuan Liang
Xiaoshuan Liang
SSShanshan Sun
Shanshan Sun
DLDalin Li
Dalin Li
The importance of long noncoding RNA (lncRNA) in tumorigenesis has been supported by increasing evidence in recent years. However, the mechanism linking lncRNA function with cancer progression remains poorly understood. lncRNA LCPAT1 plays a role in lung cancer. However, how it works in breast cancer (BC) is largely unclear. In this study, we found that LCPAT1 was highly expressed in BC tissues and cell lines. High LCPAT1 expression predicted a low survival rate in BC patients. LCPAT1 promoted BC cell proliferation, migration, and invasion while inhibiting apoptosis in vitro. LCPAT1 knockdown suppressed BC growth in vivo and vice versa. LCPAT1 interacted with RBBP4 and recruited it to the MFAP2 (microfibril-associated protein 2) promoter and then activated MFAP2 transcription. Restoration of MFAP2 rescued the effects of LCPAT1 knockdown in BC cells. In sum, LCPAT1 promotes BC progression through recruiting RBBP4 to initiate MFAP2 transcription.

31 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
YLYue Li
Yue Li
BWBaoming Wang
Baoming Wang
CWChunyang Wang
Chunyang Wang
DZDandan Zhao
Dandan Zhao
ZLZhengchuang Liu
Zhengchuang Liu
TLTao Li
Tao Li
Background: In contrast to Caucasian melanoma, which has been extensively studied, there are few studies on melanoma in Asian populations. Sporadic studies reported that only 40% of Asian melanoma patients could be druggable, which was much lower than that in Caucasians. More studies are required to refine this conclusion. Methods: Chinese melanoma patients (n = 469) were sequentially sequenced by DNA-NGS and RNA-NGS. The genomic alterations were determined, and potentially actionable targets were investigated. Results: Patients with potential druggable targets were identified in 75% of Chinese melanoma patients by DNA-NGS based on OncoKB, which was much higher than in a previous Asian study. NRG1 fusions were first identified in melanoma. In addition, up to 11.7% (7/60) of patients in the undruggable group could be recognized as actionable by including RNA-NGS analysis. By comparing the fusion detection rate between DNA-NGS and RNA-NGS, all available samples after DNA-NGS detection were further verified by RNA-NGS. The use of RNA-NGS enhanced the proportion of druggable fusions from 2.56% to 17.27%. In total, the use of RNA-NGS increased the druggable proportion from 75% to 78%. Conclusions: In this study, we systemically analyzed the actionable landscape of melanoma in the largest Asian cohort. In addition, we first demonstrated how DNA and RNA sequential sequencing is essential in bringing clinical benefits to more patients with melanoma.

14 August 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
CSChen Shuang
Chen Shuang
YWYuan Weiguang
Yuan Weiguang
FZFu Zhenkun
Fu Zhenkun
HYHuang Yike
Huang Yike
YJYang Jiankun
Yang Jiankun
DLDalin Li
Dalin Li
Toll-like receptor 5 gene polymorphism is associated with breast cancer susceptibility Toll-like receptor 5 gene polymorphism is associated with breast cancer susceptibility

11 July 2025 in Science Advances
Verified
Journal Article
Open access
LMLie Ma
Lie Ma
YZYu Zhang
Yu Zhang
ZCZixin Chen
Zixin Chen
XLXuan Liu
Xuan Liu
YWYu Wang
Yu Wang
YZYu Zhang
Yu Zhang
Chemotherapy-induced different cell fates play crucial roles in cancer treatment outcomes; however, the cross-talk between the cell fates during cancer recurrence remains unclear. Here, we found that the transition from cellular senescence to pyroptosis promoted small cell lung cancer (SCLC) recurrence after cisplatin and etoposide treatment. Parts of the senescent SCLC cells induced by chemotherapy showed positive cytoplasmic chromatin fragments (CCFs), and CCFs activated the ubiquitin-editing enzyme A20, which stabilized NLRP3 through its deubiquitinating activity, resulting in senescent cells undergoing pyroptosis. Subsequent inflammatory factors [such as interleukin-1 (IL-1)] released by pyroptosis promoted the acquisition of stem-like properties in CCF-negative senescent cells, ultimately promoting tumor recurrence. We also found that a combination of IL-1 receptor antagonist anakinra with chemotherapy delayed recurrence of SCLC, suggesting previously unidentified therapeutic strategies for SCLC.

11 February 2026 in Journal of Controlled Release
Verified
Journal Article
Closed access
HWHao Wang
Hao Wang
KMKeru Ma
Keru Ma
ZLZhenhao Li
Zhenhao Li
SLShenghan Lou
Shenghan Lou
DYDongxu Yang
Dongxu Yang
DLDalin Li
Dalin Li

11 April 2022 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
YLYue Li
Yue Li
CLChong Li
Chong Li
YJYa Jiang
Ya Jiang
XHXue Han
Xue Han
SLSisi Liu
Sisi Liu
YWYuezhen Wang
Yuezhen Wang
Programmed cell death 1 ligand 1 (PD-L1) has been approved as predictive biomarker for non-small-cell lung cancer (NSCLC) patients treated with PD-(L)1 blockade therapy. The clinical/genomic features associated with PD-L1 are not well studied. Genomic profiling of tumor biopsies from 883 Chinese NSCLC patients was performed by targeted next-generation sequencing. Immunohistochemical analysis was conducted to evaluate PD-L1 expression levels using antibodies Dako 22C3 and 28-8, respectively. Our study showed distinct correlation between PD-L1 expression and clinical/genomic characteristics when using different PD-L1 antibodies and in different histological subtypes including adenocarcinoma (ADC) and squamous cell carcinoma (SCC), respectively. PD-L1 high expression (22C3) was associated with male and lymph node metastasis only in ADC patients. Furthermore, mutations of TP53 and KRAS, KIF5B-RET fusion, copy number gains of PD-L1 and PD-L2, and arm-level amplifications of chr.12p were significantly associated with PD-L1 positive status in ADC patients. For SCC patients, the gain of EGFR and MDM2 and loss of PTPRD were negatively associated with PD-L1 expression. We also compared our results with other studies and found conflicting results presumably because of the multiplicity of antibody clones and platforms, the difference of cutoffs for assigning PD-L1 expression levels, and the variation in study populations. Our study can help to understand the utility and validity of PD-L1 as biomarker of response to immune checkpoint inhibitors.